Perinatal HPP | Infantile HPP | Childhood HPP | Total | |
---|---|---|---|---|
(n = 4) | (n = 17) | (n = 29) | (n = 50) | |
Systemic manifestations | ||||
Impairment of motor skills | 3/4 (75%) | 16/17 (94%) | 20/29 (69%) | 39/50 (78%) |
Speech developmental delay | 2/4 (50%) | 3/17 (18%) | 5/29 (17%) | 10/50 (20%) |
Failure to thrive | 2/4 (50%) | 12/17 (71%) | 17/29 (59%) | 31/50 (62%) |
Pulmonary abnormalities | 4/4 (100%) | 11/17 (65%) | 5/29 (17%) | 20/50 (40%) |
Cardiac abnormalities | 2/4 (50%) | 5/17 (29%) | 6/29 (21%) | 13/50 (26%) |
Nephrocalcinosis | 2/4 (50%) | 13/17 (76%) | 5/29 (17%) | 19/50 (38%) |
Cerebral seizures | 4/4 (100%) | 0/17 (0%) | 0/29 (0%) | 4/50 (8%) |
Gastrointestinal abnormalities | 3/4 (75%) | 7/17 (41%) | 6/29 (21%) | 16/50 (32%) |
Musculoskeletal pain | 1/4 (25%) | 7/17 (41%) | 16/29 (55%) | 24/50 (48%) |
Difficulties in swallowing | 2/4 (50%) | 7/17 (41%) | 8/29 (28%) | 17/50 (34%) |
Osseous manifestations | ||||
Impairment of mineralization | 4/4 (100%) | 15/17 (88%) | 18/29 (62%) | 36/50 (72%) |
Pathologic fractures | 1/4 (25%) | 4/17 (24%) | 1/29 (3%) | 6/50 (12%) |
Chronic non-bacterial osteomyelitis/osseous inflammation | 0/4 (0%) | 4/17 (24%) | 3/29 (10%) | 7/50 (14%) |
Craniosynostosis | 3/4 (75%) | 13/17 (76%) | 8/29 (28%) | 24/50 (48%) |
Dental manifestations | ||||
Premature loss-of-teeth | 2/4 (50%) | 10/17 (59%) | 20/29 (69%) | 32/50 (64%) |
Caries/deficient enamel | 1/4 (25%) | 2/17 (12%) | 7/29 (24%) | 10/50 (20%) |